A61K 2039/545
Medicinal preparations containing antigens or antibodies: characterised by the dose, timing or
Official title: {characterised by the dose, timing or administration schedule}
A61K2039/545 (Medicinal preparations containing antigens or antibodies: characterised by the dose, timing or) appears on 4,047 US grants and 9,749 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,047
- Published applications
- 9,749
- Assignees
- 2,796
- Inventors
- 17,184
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 4 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 6 | 0 |
| 1997 | 10 | 0 |
| 1998 | 14 | 0 |
| 1999 | 11 | 0 |
| 2000 | 20 | 0 |
| 2001 | 19 | 12 |
| 2002 | 22 | 53 |
| 2003 | 25 | 95 |
| 2004 | 27 | 112 |
| 2005 | 24 | 120 |
| 2006 | 26 | 105 |
| 2007 | 30 | 91 |
| 2008 | 37 | 119 |
| 2009 | 49 | 172 |
| 2010 | 56 | 176 |
| 2011 | 66 | 207 |
| 2012 | 89 | 193 |
| 2013 | 87 | 197 |
| 2014 | 132 | 223 |
| 2015 | 152 | 318 |
| 2016 | 166 | 393 |
| 2017 | 209 | 481 |
| 2018 | 260 | 464 |
| 2019 | 262 | 533 |
| 2020 | 331 | 649 |
| 2021 | 297 | 751 |
| 2022 | 320 | 839 |
| 2023 | 302 | 874 |
| 2024 | 329 | 979 |
| 2025 | 378 | 854 |
| 2026 | 261 | 739 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof6 Oct 2026US 12,753,234 B2Purdue Research Foundation
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- Method for inducing an immune response8 Oct 2026US 2026/0306617 A1Acclarent, Inc.
- Treatment of peanut allergy with tolerizing nanoparticles8 Oct 2026US 2026/0306622 A1Cour Pharmaceuticals Development Company, Inc.
Most cited
By later US patents
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody199US 6,455,043 B1IDEC Pharmaceuticals Corporation · 2002
- Antibody purification179US 7,863,426 B2Abbott Biotechnology Ltd. · 2011
- Method for muscle delivery of drugs, nucleic acids and other compounds166US 6,958,060 B2Genetronics, Inc. · 2005